210 related articles for article (PubMed ID: 20722788)
1. Recreational use of phosphodiesterase type 5 inhibitors by healthy young men.
Bechara A; Casabé A; De Bonis W; Helien A; Bertolino MV
J Sex Med; 2010 Nov; 7(11):3736-42. PubMed ID: 20722788
[TBL] [Abstract][Full Text] [Related]
2. Recreational use of PDE5 inhibitors by young healthy men: recognizing this issue among medical students.
Korkes F; Costa-Matos A; Gasperini R; Reginato PV; Perez MD
J Sex Med; 2008 Oct; 5(10):2414-8. PubMed ID: 18331258
[TBL] [Abstract][Full Text] [Related]
3. Characteristics, behaviors, and attitudes of men bypassing the healthcare system when obtaining phosphodiesterase type 5 inhibitors.
Schnetzler G; Banks I; Kirby M; Zou KH; Symonds T
J Sex Med; 2010 Mar; 7(3):1237-46. PubMed ID: 20136707
[TBL] [Abstract][Full Text] [Related]
4. Profiling characteristics of men who use phosphodiesterase type 5 inhibitors based on obtaining patterns: data from the nationwide Japanese population.
Kimura M; Shimura S; Kobayashi H; Tai T; Chikano Y; Baba S; Kano M; Nagao K
J Sex Med; 2012 Jun; 9(6):1649-58. PubMed ID: 22513057
[TBL] [Abstract][Full Text] [Related]
5. An Evaluation of a Clinical Care Pathway for the Management of Men With Nonorganic Erectile Dysfunction.
Jenkins LC; Hall M; Deveci S; Guhring P; Parker M; Nelson CJ; Mulhall JP
J Sex Med; 2019 Oct; 16(10):1541-1546. PubMed ID: 31444103
[TBL] [Abstract][Full Text] [Related]
6. Recreational use of erectile dysfunction medications and its adverse effects on erectile function in young healthy men: the mediating role of confidence in erectile ability.
Harte CB; Meston CM
J Sex Med; 2012 Jul; 9(7):1852-9. PubMed ID: 22568639
[TBL] [Abstract][Full Text] [Related]
7. A 6 month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Latin American men with erectile dysfunction.
Rubio-Aurioles E; Reyes LA; Borregales L; Cairoli C; Sorsaburu S
Curr Med Res Opin; 2013 Jun; 29(6):695-706. PubMed ID: 23540375
[TBL] [Abstract][Full Text] [Related]
8. A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction.
El-Meliegy A; Rabah D; Al-Mitwalli K; Mostafa T; Hussein T; Istarabadi M; Lei Y; Gurbuz S
Curr Med Res Opin; 2013 Jun; 29(6):707-17. PubMed ID: 23540436
[TBL] [Abstract][Full Text] [Related]
9. Off-Label Use of Phosphodiesterase Type 5 Inhibitor Erectile Dysfunction Medication to Enhance Sex Among Gay and Bisexual Men in Australia: Results From the FLUX Study.
Hammoud MA; Jin F; Lea T; Maher L; Grierson J; Prestage G
J Sex Med; 2017 Jun; 14(6):774-784. PubMed ID: 28583339
[TBL] [Abstract][Full Text] [Related]
10. The EPIFARM study: an observational study in 574 community pharmacies in Spain characterizing patient profiles of men asking for erectile dysfunction medication.
Morales AM; Ibáñez J; Machuca M; Pol-Yanguas E; Schnetzler G; Renedo VP
J Sex Med; 2010 Sep; 7(9):3153-60. PubMed ID: 20584119
[TBL] [Abstract][Full Text] [Related]
11. Combination of vacuum erection device and PDE5 inhibitors as salvage therapy in PDE5 inhibitor nonresponders with erectile dysfunction.
Canguven O; Bailen J; Fredriksson W; Bock D; Burnett AL
J Sex Med; 2009 Sep; 6(9):2561-7. PubMed ID: 19627462
[TBL] [Abstract][Full Text] [Related]
12. Potential for Long-Term Benefit of Cognitive Behavioral Therapy as an Adjunct Treatment for Men with Erectile Dysfunction.
Khan S; Amjad A; Rowland D
J Sex Med; 2019 Feb; 16(2):300-306. PubMed ID: 30770073
[TBL] [Abstract][Full Text] [Related]
13. [Do phosphodiesterase type 5 inhibitors generics enhance discontinuation due to price with patients suffering from erectile dysfunction?].
Baydaroglu E; Eschwège P; Hubert J; El Osta R
Prog Urol; 2019; 29(6):326-331. PubMed ID: 31151915
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and detection rate of underlying disease in men with erectile dysfunction receiving phosphodiesterase type 5 inhibitors in the United Kingdom: a retrospective database study.
Kirby MG; Schnetzler G; Zou KH; Symonds T
Int J Clin Pract; 2011 Jul; 65(7):797-806. PubMed ID: 21676121
[TBL] [Abstract][Full Text] [Related]
15. PDE5 inhibitors: considerations for preference and long-term adherence.
Smith WB; McCaslin IR; Gokce A; Mandava SH; Trost L; Hellstrom WJ
Int J Clin Pract; 2013 Aug; 67(8):768-80. PubMed ID: 23869678
[TBL] [Abstract][Full Text] [Related]
16. Men with mild erectile dysfunction benefit from sildenafil treatment.
Bénard F; Carrier S; Lee JC; Talwar V; Defoy I
J Sex Med; 2010 Nov; 7(11):3725-35. PubMed ID: 20946161
[TBL] [Abstract][Full Text] [Related]
17. Newer phosphodiesterase inhibitors: comparison with established agents.
McNamara ER; Donatucci CF
Urol Clin North Am; 2011 May; 38(2):155-63. PubMed ID: 21621082
[TBL] [Abstract][Full Text] [Related]
18. PDE-5 inhibitors in monotherapy versus combination therapy in a sample of 1200 patients with erectile dysfunction.
Labairu-Huerta L; Padilla-Fernández B; Arrondo-Arrondo JL; Valverde-Martínez LS; Martín-Rodríguez A; Silva-Abuín JM; García-Cenador MB; Mirón-Canelo JA; Lorenzo-Gómez MF
Arch Ital Urol Androl; 2015 Sep; 87(3):204-9. PubMed ID: 26428641
[TBL] [Abstract][Full Text] [Related]
19. PDE5 inhibitor treatment persistence and adherence in Brazilian men: post-hoc analyses from a 6-month, prospective, observational study.
Cairoli C; Reyes LA; Henneges C; Sorsaburu S
Int Braz J Urol; 2014; 40(3):390-9. PubMed ID: 25010306
[TBL] [Abstract][Full Text] [Related]
20. Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients.
Lombardi G; Macchiarella A; Cecconi F; Del Popolo G
J Sex Med; 2009 May; 6(5):1248-58. PubMed ID: 19210710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
